Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: Wiley Matthew T.
BioXcel Therapeutics, Inc. (BTAI)
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
BTAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BTAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BTAI alerts
High impacting BioXcel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BTAI
News
- BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s DementiaGlobeNewswire
- BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024GlobeNewswire
- Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know [Yahoo! Finance]Yahoo! Finance
- BioXcel Therapeutics to Present at ThinkEquity ConferenceGlobeNewswire
- BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
BTAI
Earnings
- 8/6/24 - Beat
BTAI
Sec Filings
- 10/9/24 - Form 8-K
- 10/3/24 - Form 4
- 10/3/24 - Form 4
- BTAI's page on the SEC website